Immunovaccine to study DPX-Survivac in Phase II combination trial for DLBCL

Canadian-based immuno-oncology company Immunovaccine is set to evaluate its DPX-Survivac in combination with a PD-1 checkpoint inhibitor and a low-dose cyclophosphamide in its Phase II clinical trial to treat measurable or recurrent diffuse large B-C …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news